Cambium Bio Limited (ASX:CMB), a Sydney-based clinical-stage regenerative medicine company, has reported that all nine resolutions put to shareholders at its 2026 Annual General Meeting held on 9 November 2026 were carried, with a tenth conditional resolution not required.

Key Points

  • All resolutions were decided by way of poll at the AGM held on 9 November 2026
  • Resolutions 1 through 9 were carried; Resolution 10 (conditional board spill) was not required
  • Shareholders approved the issue of up to A$10,000,000 worth of shares under Resolution 9
  • The re-election of Director Dr Edmund Kemp Waller was carried with 100.00% of votes cast in favour
  • Placement share issues to named parties including Mr Chun Yi Wu, Ms Yi Chi Wu, Zheng Yang Biomedical Technology Co. Ltd, and Ms Shu-Chin Hsu were approved

AGM Voting Results and Resolutions Carried

All resolutions put to the meeting were decided by poll in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. The Remuneration Report adoption under Resolution 1 was carried with 99.98% of votes cast in favour. The ratification of the prior issue of 2,100,000 shares under Listing Rule 7.1A was approved under Resolution 3, with 99.99% of votes cast in favour. Resolutions 4A, 4B, and 4C ratified prior issues of 2,000,000 options, 120,000 options, and 40,000 options respectively under Listing Rule 7.1, each carried with 99.99% of votes cast in favour.

Director Re-election and Placement Share Approvals

Resolution 2, the re-election of Director Dr Edmund Kemp Waller, was carried with 21,189,445 votes in favour, representing 100.00% of votes cast on the poll. Resolution 5 approved the issue of placement shares to Mr Chun Yi Wu and Ms Yi Chi Wu under section 611 item 7 of the Corporations Act, carried with 99.95% of votes cast in favour. Resolution 6 approved the issue of placement shares to Zheng Yang Biomedical Technology Co. Ltd under Listing Rule 10.11, carried with 99.91% of votes in favour. Resolution 7 approved the issue of placement shares to Ms Shu-Chin Hsu under Listing Rule 7.1, also carried with 99.95% of votes cast in favour.

Additional Placement Capacity and Share Issue Authority

Resolution 8 approved additional placement capacity under Listing Rule 7.1A, receiving 99.95% of votes cast in favour with 21,518,607 votes for and 9,728 against. Resolution 9 approved the issue of up to A$10,000,000 worth of shares, also carried with 99.95% of votes in favour. The conditional Resolution 10, which would have required a board spill, was not required following the outcome of Resolution 1 on the Remuneration Report. The filing was authorised by the Company Secretary of Cambium Bio Limited.